的新兴和新兴药疗法:系统审查和网络元分析
Han Li1, Anita Arthur2, Mahtab Forouzandeh2
1From the University of Florida College of Medicine, Gainesville, Florida, USA.
Dermatitis : contact, atopic, occupational, drug
|June 20, 2025
概括
新型疗法如乌斯特基努马布,伊克齐祖马布,乌帕达西提尼布,阿布罗西提尼布,巴里西提尼布,尼莫利祖马布和杜皮卢马布在治疗与皮肤病相关的慢性症方面表现出显著的疗效,通常具有轻微的副作用.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 慢性严重影响患者的生活质量.
- 现有的审查缺乏对新兴的治疗方法的标准化疗效指标.
- 新型治疗药物为治疗严重的状况提供了潜在的潜力.
研究的目的:
- 对常见的性皮肤病的新型治疗方法的疗效和安全性进行评估.
- 建立一个标准化的衡量标准,用于在不同研究中比较治疗有效性.
- 确定慢性的新兴主要疗法.
主要方法:
- 从主要数据库 (PubMed,科学网络,Embase,Cochrane) 中对II/III期临床试验 (2015-2023) 的系统审查.
- 标准化疗效度量:在数值评分尺度上实现≥4分减少的患者比例.
- 对不良影响和治疗中止率的分析.
主要成果:
- 乌斯特基努马布和ixekizumab在牛皮病中表现出强烈的疗效.
- 乌帕帕西提尼布,阿布罗西提尼布和巴里西提尼布在亚托皮炎中显示出显著的改善.
- 尼莫利祖马布和杜皮卢马布对结节炎有效,但对比数据有限.
- 副作用通常是轻微的,在各种药物之间是可比的;观察到的停药率很低.
结论:
- 新型药物,包括JAK抑制剂和生物药物,代表了慢性管理的重大进步.
- 标准化疗效评估强调了牛皮,亚托皮性皮肤炎和节炎的关键治疗方法.
- 新兴疗法为患有慢性性皮肤疾病的患者提供了更好的生活质量.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
267
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
267
01:25Analgesia and Pain Management
822
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
822